Juan P. Alderuccio, MD, is an associate professor of medicine and clinical site disease group leader in the Lymphoma Section at Sylvester Comprehensive Cancer Center, University of Miami Health System.
This final segment highlights practical lessons learned from implementing bispecific antibody therapies and explores how the field may evolve in the coming years. Panelists emphasize that optimizing outcomes requires multidisciplinary collaboration, standardized protocols, and continuous education across clinical teams.
This segment centers on how to maintain continuity of care when patients start bispecific antibodies at an academic center and then transition to community-based treatment, with an emphasis on communication, logistics, and patient engagement.
This segment focuses on practical strategies for early recognition and management of CRS in the outpatient setting, along with approaches to prevent infections during bispecific antibody therapy. The panel emphasizes that patient education and clear care pathways are critical for safely managing treatment outside the hospital.
Learn how clinicians spot and grade CRS and ICANS early on bispecific antibodies, using home vitals, caregiver alerts, and rapid steroid/toci pathways.
Standardize bispecific antibody infusions with nursing training, CRS monitoring, pharmacy checks, and clear academic-community handoffs
Learn how clinicians set bispecific immunotherapy expectations, manage early side effects, and decide on outpatient vs inpatient care and monitoring.
Experts outline how to start bispecific therapy for relapsed DLBCL, manage CRS/ICANS, and coordinate community–academic lymphoma care.
Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.
Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.
Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.
